Telbivudine
Pronouncation: (tel-BI-vyoo-deen)Class: Antiviral
Trade Names:
Tyzeka
- Tablets 600 mg
Pharmacology
Feedback for Telbivudine
Compare with other drugs. |
Telbivudine is phosphorylated by cellular kinases to the active triphosphate form. The telbivudine 5‐triphosphate is incorporated into viral DNA, causing DNA chain termination that results in inhibition of hepatitis B virus (HBV) replication.
Pharmacokinetics
Absorption
C max is approximately 3.7 mcg/mL. Steady state is achieved after approximately 5 to 7 days and occurred between 1 and 4 h.
Distribution
Plasma protein binding is low (3.3%). Vd exceeds total body water, suggesting wide distribution into tissues.
Metabolism
Metabolites were not detected.
Elimination
Terminal t ½ is 40 to 49 h. Elimination is primarily as unchanged drug in the urine.
Indications and Usage
Treatment of chronic hepatitis B in adults with evidence of viral replication and either evidence of persistent elevations in serum aminotransaminases or histologically active disease.
Contraindications
Standard considerations.
Dosage and Administration
Adults and adolescents 16 yr of age and olderPO 600 mg once daily.
Renal Function ImpairmentAdults and adolescents 16 yr of age and older
PO CrCl 30 to 49 mL/min: 600 mg once every 48 h. CrCl less than 30 (not requiring dialysis): 600 mg once every 72 h. End-stage renal disease: 600 mg once every 96 h.
Storage/Stability
Store in original container at 59° to 86°F.
Drug Interactions
Drugs that alter renal functionMay alter telbivudine plasma concentrations.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Fatigue, malaise (12%); headache (11%); dizziness, pyrexia (4%); insomnia (3%).
Dermatologic
Rash (4%).
EENT
Nasopharyngitis (11%); pharyngolaryngeal pain (5%).
GI
Diarrhea/loose stools, nausea, vomiting (7%); dyspepsia (3%).
Hematologic-Lymphatic
Neutropenia (2%); thrombocytopenia (less than 1%).
Lab Tests
Increased CPK (9%); increased ALT (4%); increased AST (3%); elevated lipase (2%).
Musculoskeletal
Arthralgia, back pain (4%); myalgia (3%).
Respiratory
Upper respiratory tract infection (14%); cough (7%).
Miscellaneous
Abdominal pain (12%); influenza and influenza-like symptoms, postprocedural pain (7%).
Precautions
WarningsLactic acidosis and severe hepatomegaly with steatosis and death have been reported with use of nucleoside analogs. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued telbivudine. |
Pregnancy
Category B .
Lactation
Undetermined.
Children
Safety and efficacy not established in children younger than 16 yr of age.
Elderly
Use with caution, considering the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
Renal Function
Dose adjustment is recommended in patients with CrCl less than 50 mL/min.
Exacerbation of hepatitis
Severe acute exacerbations of hepatitis B have occurred after discontinuation of anti-hepatitis B therapy.
Lamivudine-resistant hepatitis B
No adequate studies are available for telbivudine treatment of patients with established lamivudine-resistant HBV infection.
Liver transplant patients
Safety and efficacy of telbivudine in liver transplant patients not established.
Myopathy
Has been reported several weeks to months after starting therapy.
Overdosage
Symptoms
No adverse reactions were noted with doses up to 1,800 mg/day for 4 days.
Patient Information
- Advise patients to read the patient information leaflet before using product the first time and with each refill.
- Inform patients that they will be under the care of a health care provider while taking telbivudine and to discuss any new symptoms.
- Advise patients to promptly report unexplained muscle weakness, tenderness, or pain.
- Explain to patients that telbivudine is not a cure for hepatitis B and that the long-term benefits and relationship of treatment response to outcome are unknown.
- Inform patients that deterioration of liver disease may occur in some cases if treatment is discontinued and to discuss any changes in their regimen with a health care provider.
- Inform patients that treatment has not been shown to reduce HBV transmission through sexual contact.
| Link to this page | ![]() |
Printable Version | ![]() |
Email Page | ![]() |
Add to my drug list |













